Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ULTRAM ER vs ACTIQ
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Tramadol is a centrally acting synthetic opioid analgesic that binds to μ-opioid receptors and inhibits serotonin and norepinephrine reuptake.
Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.
Management of moderate to moderately severe chronic pain in adults requiring around-the-clock treatment
Management of breakthrough pain in cancer patients aged 16 and older who are already receiving and tolerant to opioid therapy for their underlying persistent cancer pain
100 mg orally once daily initially, titrate up to 100 mg twice daily as needed; maximum 200 mg/day.
200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.
The terminal elimination half-life of tramadol is approximately 6.3 hours (range 5-9 hours), while its active metabolite M1 has a half-life of about 7.4 hours. Clinically, this supports dosing every 24 hours for the extended-release formulation.
Terminal half-life 0.83–2 hours (mean 1.3 h) in adults; note that context: transmucosal absorption leads to rapid onset but short duration; half-life is not correlated with clinical effect due to oral transmucosal route and rapid redistribution.
Metabolized primarily via CYP2D6 and CYP3A4; O-desmethyltramadol (M1) is the active metabolite formed by CYP2D6; tramadol and metabolites undergo further conjugation.
Primarily hepatic via CYP3A4 to inactive metabolites (norfentanyl, despropionylfentanyl, hydroxyfentanyl) and other metabolites; <7% excreted unchanged in urine.
Renal excretion of tramadol and its metabolites accounts for approximately 90% of total elimination. About 10% is excreted unchanged, 30% as O-desmethyltramadol (M1), and the remainder as other minor metabolites. Biliary/fecal excretion is minimal (<10%).
Primarily renal as metabolites (about 75% as metabolites, <10% unchanged). Fecal excretion accounts for <9%. Biliary excretion is minor.
Approximately 20% bound to plasma proteins, primarily albumin.
Fentanyl is 80–85% bound to plasma proteins (primarily albumin and α1-acid glycoprotein).
Volume of distribution is approximately 2.6-3.0 L/kg, indicating extensive tissue distribution beyond plasma volume.
Approximately 4 L/kg (range 3–6 L/kg); large Vd indicates extensive tissue distribution and redistribution contributing to short duration.
Oral bioavailability of tramadol is approximately 75% after a single dose, increasing to 90-100% upon multiple dosing due to saturable first-pass metabolism. For ULTRAM ER, bioavailability is comparable to immediate-release formulations.
Oral transmucosal: 50% (range 47–54%) relative to IV; variable and enhanced by rapid absorption through buccal mucosa.
GFR 30-80 m L/min: no adjustment; GFR <30 m L/min: avoid or extend dosing interval to 12 hours; not recommended in GFR <15 m L/min.
No specific GFR-based dose adjustment recommended; use with caution in severe renal impairment (Cr Cl < 30 m L/min) and consider dose reduction due to potential accumulation.
Child-Pugh Class A or B: use with caution, consider reducing total daily dose by 50%; Child-Pugh Class C: contraindicated.
Child-Pugh Class A/B: No adjustment. Child-Pugh Class C: Reduce initial dose to 100 mcg and titrate slowly; monitor closely for prolonged effects.
Not recommended for use in pediatric patients <18 years due to risk of respiratory depression and lack of safety data.
Not approved for pediatric use; safety and efficacy not established in patients under 16 years.
Start at lowest dose (100 mg once daily); titrate cautiously; monitor for CNS and respiratory depression; consider reduced clearance in elderly.
Initiate at 100 mcg transmucosally; titrate slowly due to increased sensitivity and risk of respiratory depression. Monitor for adverse effects.
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion in children can be fatal; neonatal opioid withdrawal syndrome; risk of medication errors with other tramadol products; interactions with CNS depressants; serotonin syndrome; contraindicated in patients with significant respiratory depression; contraindicated in patients with acute or severe bronchial asthma; contraindicated in patients with known or suspected gastrointestinal obstruction; contraindicated in patients with previous hypersensitivity to tramadol.
Risk of respiratory depression, addiction, abuse, and misuse; accidental ingestion can be fatal; concomitant use with benzodiazepines or CNS depressants may cause profound sedation, respiratory depression, coma, and death; not for use in opioid non-tolerant patients; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; serious, life-threatening, or fatal respiratory depression may occur even at recommended doses.
Risk of respiratory depression; risk of serotonin syndrome with serotonergic drugs; risk of seizures especially in patients with epilepsy or risk factors; risk of adrenal insufficiency; risk of severe hypotension; risk of abuse and dependence; avoidance of abrupt discontinuation; use in renal or hepatic impairment; use in elderly; use in pregnancy and breastfeeding.
Risk of respiratory depression; addiction, abuse, and misuse; interactions with CNS depressants; serotonin syndrome; adrenal insufficiency; severe hypotension; seizures; withdrawal; use in patients with head injuries, increased intracranial pressure, biliary tract disease, pancreatitis; risk of choking with lozenge; oral mucosal irritation; dental caries; hypokalemia; hyponatremia; use in elderly, cachectic, or debilitated patients.
Hypersensitivity to tramadol or any formulation component; significant respiratory depression; acute or severe bronchial asthma in unmonitored settings; known or suspected gastrointestinal obstruction; concurrent use of MAOIs or within 14 days; use in children <12 years; use in children <18 years after tonsillectomy/adenoidectomy; use in patients with severe hepatic impairment.
Significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment; known or suspected paralytic ileus; hypersensitivity to fentanyl or any component; opioid non-tolerant patients; management of acute or postoperative pain including headache/migraine, dental pain, or emergency department use.
Avoid alcohol. No specific food restrictions; however, taking with food may reduce nausea. Grapefruit juice may increase tramadol levels; consider limiting grapefruit intake.
No significant food interactions. Grapefruit juice may increase fentanyl levels, but specific studies with ACTIQ are lacking. Avoid alcohol, as it may increase sedation and respiratory depression risk.
Pregnancy category C. First trimester: Limited data; avoid unless benefit outweighs risk due to potential neural tube defects. Second and third trimesters: Fetal dependence, neonatal withdrawal syndrome (seizures, irritability, respiratory depression) if used >7 days. Increased risk of preterm birth and low birth weight.
FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause neonatal opioid withdrawal syndrome; avoid use during labor due to risk of neonatal respiratory depression.
Ultram ER has an M/P ratio of 0.7-1.3. Small amounts excreted; can cause infant sedation and constipation. Use caution; monitor infant for drowsiness or feeding difficulties.
Excreted in breast milk; M/P ratio not established. Limited data suggest low levels, but risk of infant sedation and respiratory depression. Avoid use while breastfeeding unless potential benefit outweighs risk.
No established dose adjustments; pharmacokinetics may change in pregnancy (increased clearance, distribution volume). Use lowest effective dose; avoid sustained release if possible. Caution in third trimester due to risk of neonatal withdrawal.
Due to increased plasma volume and hepatic metabolism in pregnancy, dose requirements may increase; adjust based on clinical response and tolerance. Avoid use during labor and delivery due to risk of neonatal respiratory depression; short-term use preferred.
ULTRAM ER contains tramadol, an opioid agonist with SNRI properties. Do not crush or chew extended-release tablets; this can cause rapid release and fatal overdose. Use with caution in patients with seizure disorders or those taking SSRIs, SNRIs, MAOIs, or other drugs that lower seizure threshold. Avoid concurrent use with alcohol or CNS depressants. Monitor for serotonin syndrome when combined with serotonergic drugs. Do not discontinue abruptly after prolonged use; taper to avoid withdrawal symptoms. Not recommended for patients under 18. Crushing extended-release tablets is a safety hazard.
ACTIQ is a transmucosal immediate-release fentanyl formulation indicated for breakthrough cancer pain in opioid-tolerant patients. Initiate with the lowest strength (200 mcg) and titrate upward. Avoid use in opioid-naive patients due to risk of fatal respiratory depression. Place the unit between cheek and lower gum, not sublingually. Instruct patient not to bite or suck the unit. Monitor for sedation and respiratory depression. Multiple units may be used per episode if needed, but wait at least 4 hours before next episode. Dispose of partially used units by flushing down toilet.
Take ULTRAM ER exactly as prescribed, usually once daily. Swallow tablets whole; do not crush, chew, or break them.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, sedatives) while taking this medication.,This medication has a risk of addiction, abuse, and misuse. Store securely and dispose of unused tablets properly.,Do not stop taking this medicine suddenly; withdrawal symptoms may occur. Follow your doctor's instructions for tapering.,Seek emergency medical help if you have trouble breathing, severe drowsiness, or slow heartbeat.,Inform your doctor if you have a history of seizures, head injury, or are taking antidepressants like MAOIs, SSRIs, or SNRIs.,ULTRAM ER may cause constipation, nausea, dizziness, or drowsiness. Increase fluid intake and fiber to prevent constipation.,Keep out of reach of children and pets. Accidental ingestion can be fatal.,Do not drive or operate heavy machinery until you know how ULTRAM ER affects you.
Only use ACTIQ if you are already taking regular around-the-clock opioid pain medicine and are tolerant to opioids.,Do not use ACTIQ for short-term pain like after surgery, headache, or dental pain.,Place the unit in your cheek pouch, not under your tongue. Do not chew or suck it.,If you need more than 4 units per day, contact your doctor as your dose may need adjustment.,Store ACTIQ in a safe place away from children, as accidental ingestion can be fatal.,Dispose of unused or partially used units by flushing them down the toilet.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ULTRAM ER vs ACTIQ, answered by our medical review team.
ULTRAM ER is a Opioid Analgesic that works by Tramadol is a centrally acting synthetic opioid analgesic that binds to μ-opioid receptors and inhibits serotonin and norepinephrine reuptake.. ACTIQ is a Opioid Analgesic that works by Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ULTRAM ER and ACTIQ depend on the specific clinical indication. These are both Opioid Analgesic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ULTRAM ER is: 100 mg orally once daily initially, titrate up to 100 mg twice daily as needed; maximum 200 mg/day.. The standard adult dose of ACTIQ is: 200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ULTRAM ER and ACTIQ in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ULTRAM ER is classified as Category C. Pregnancy category C. First trimester: Limited data; avoid unless benefit outweighs risk due to potential neural tube defects. Second and third trimesters: Fetal dependence, neonat. ACTIQ is classified as Category C. FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.